Clinical Trial

Cost-Benefit Ratio – EMA to harmonise HTA processes

04.11.2010

London – While looking for a successor to EMA Executive Director Thomas Lönngren, the agency has opened a debate on a hot topic for biopharmaceutical companies and health technology assessors – defining the rules for what kinds of evidence must be provided to determine a drug candidate’s risk-benefit balance and its economic value. Although the EMA says it is not aiming to establish a Euro-NICE, more harmonisation could lower hurdles for drug developers in reaching EU markets. It could also bring down R&D costs for candidate drugs in early development.
AstraZeneca, GlaxoSmith­Kline and Johnson & Johnson are now funding a four-month pilot discussion looking at diabetes treatment that will include clini­cians, health technology assessors, pa­tient groups, payers, regulators and drug developers from France, Germany, Italy, the Netherlands, Sweden and the UK. Partici­pants believe the experiment could help shape subsequent pilots, and broaden initiatives for early consultation. How­ever, recommendations from the October meeting and two further discussions will be non-binding.
Advice for the developers of novel medicines is urgently needed in markets where pressure to control healthcare costs is on the rise. The EMA has been working closely with HTA bodies since 2008 to determine how clinical trials must be designed to provide data that allow evaluation of the risk-benefit ratio of a compound, as well as the comparison of a drug’s relative effectiveness and benefit-cost ratio.

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1982

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/cost-benefit-ratio-ema-to-harmonise-hta-processes.html

Product of the week

Products

Events

All Events

Current issue

All issues